Kava (Piper methysticum)
Kavalactones; Pacific 'awa' and the libido question
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA approved; subject of a 2002 FDA hepatotoxicity advisory
Reference only. Not medical advice.
What can go wrong
Hepatotoxicity is the defining concern: clusters of severe liver injury led to bans in Germany and elsewhere and a 2002 FDA consumer advisory; risk factors implicated include non-noble (tudei) cultivars, aerial-plant parts, solvent extraction, and co-use with alcohol/hepatotoxic drugs. Heavy chronic use causes reversible scaly 'kava dermopathy,' and acute intoxication impairs driving. Additive sedation with alcohol and benzodiazepines is a real interaction.
This is something to take to a clinician. The Atlas can tell you what is known about kava (piper methysticum) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Kava is the root of Piper methysticum, the ceremonial and social beverage of much of the Pacific ('awa,' 'yaqona'), whose psychoactivity comes from six main kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin) acting on GABA, voltage-gated channels, and monoamine systems. Its relevance to male sexual health is double-edged: kava is a genuine anxiolytic (supported by meta-analyses for generalized anxiety), which can help performance-anxiety-driven dysfunction, but heavy chronic use is associated in Pacific ethnographic and clinical reports with reduced libido and a characteristic 'kava dermopathy.' It also carries a contested but real hepatotoxicity signal that triggered bans and an FDA advisory.
An anxiolytic Pacific root that can cut anxiety-driven dysfunction - and, at chronic high use, blunt libido.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Kavalactones potentiate GABA-A signaling, block voltage-gated sodium/calcium channels, inhibit monoamine-oxidase-B and noradrenaline reuptake, and modulate dopamine - producing anxiolysis and mild euphoria without classic sedative dependence. The sexual relevance is indirect: reducing anxiety can improve psychogenic erectile and arousal problems, while chronic heavy intake appears to dampen sexual interest, plausibly via dopaminergic and general CNS depressant effects.
Kavalactones are substituted alpha-pyrones (6-styryl-4-methoxy-2-pyranones). The relative ratio of the six lactones (the 'chemotype') differs by cultivar and strongly influences effects; 'noble' cultivars are traditionally preferred over 'tudei' types linked to nausea and possibly more toxicity.
Anxiolytic helper, chronic-use libido suppressor
Kava is one of the few entries here whose sexual-health story cuts both ways: it can relieve the anxiety that drives psychogenic dysfunction, yet Pacific reports and some users describe reduced libido with heavy chronic consumption. It is not an aphrodisiac; at best it removes an anxiety barrier, at worst it suppresses desire.
Safety in detail
- Reports of severe hepatotoxicity; bans/restrictions and FDA 2002 advisory
- Kava dermopathy with heavy chronic use
- Additive CNS depression with alcohol/benzodiazepines
- Reduced libido reported with chronic heavy consumption
What people get wrong
Often saidKava is a libido-boosting aphrodisiac
ActuallyKava is an anxiolytic, not an aphrodisiac; it may help anxiety-driven dysfunction, but chronic heavy use is associated with reduced libido.
Often saidNatural means no liver risk
ActuallyKava carries a documented, if debated, hepatotoxicity signal that led to bans and an FDA advisory.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Kava has been the central ceremonial and social drink of Melanesia, Polynesia, and Micronesia for millennia, with deep ritual significance in Fiji, Vanuatu, Tonga, Samoa, and Hawai'i. Western interest swung from 1990s anxiety-supplement enthusiasm to 2000s hepatotoxicity bans, and more recently to a kava-bar revival in the US.
The people taking it
Heavily consumed across the Pacific; exported as dried root, instant powders, and extracts; sold in Western 'calm' supplements and a growing kava-bar scene. Regulatory status varies from banned/restricted to legal depending on country and era.
What we do not know
- Does anxiolysis from kava produce measurable improvement in psychogenic ED, net of its libido-dampening risk?
- How much of the hepatotoxicity signal is cultivar/plant-part/solvent-specific versus intrinsic?
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Cultivar matters: 'noble' kava is preferred for safety/quality, while cheaper 'tudei' cultivars and aerial parts are linked to worse tolerability and possibly higher hepatotoxic risk; adulteration and mislabeling of cultivar/plant-part occur.
At a glance
- Family
- Piperaceae
- Part used
- Root/rhizome
- Actives
- Six major kavalactones
- Anxiolytic evidence
- Cochrane meta-analysis (modest GAD benefit)
- Safety flag
- Hepatotoxicity reports; FDA 2002 advisory
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Kava (Piper methysticum). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Pittler & Ernst, Cochrane review of kava for anxiety2003 (updated)
Kava extract modestly superior to placebo for generalized anxiety symptoms
Sarris et al., Kava Anxiety Depression Spectrum/RCT2009-2013
Standardized aqueous kava reduced anxiety in RCTs; later trial more equivocal, with liver monitoring
Hepatotoxicity case-series and regulatory reviews2000s
Cases of severe liver injury prompted European bans and the FDA advisory; causality and cofactors remain debated